Acute radiodermatitis in cancer patients: incidence and severity estimates

Bontempo, Priscila de Souza Maggi; Ciol, Márcia A.; Menêses, Amanda Gomes de; Simino, Giovana Paula Rezende; Ferreira, Elaine Barros; Reis, Paula Elaine Diniz dos

doi:10.1590/s1980-220x2019021703676

Cited by 22 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to this study, the first appearance of RD was approximately 11 days (24). In current study, in patients with grade 1 RD and not progressing to grade 2 or 3; the starting dose of grade 1 RD is 32 Gy (range, 16-56).…”

Section: Discussionmentioning

confidence: 66%

Factors on development and severity of acute radiodermatitis: prospective single-center study

İnan

Arslan

Aral

et al. 2022

Anatolian Current Medical Journal

View full text Add to dashboard Cite

Aim: Although prior literature has examined the treatment and patient-associated factors affecting the development and severity of acute radiodermatitis, there are relatively few prospective studies evaluating both. This study was prospectively designed to evaluate factors affecting the development and extent of radiation-induced acute skin toxicity called radiodermatitis (RD). Material and Method: A total of 63 patients who underwent radiotherapy (RT) in Ankara Atatürk Research and Education Hospital between July 2017 and October 2018 were evaluated. Patients’ demographic status, disease/treatment details, hemoglobin, ferritin, folic acid, Vit B12, and hemoglobin A1c values were recorded. The development and grade of RD were evaluated weekly by the same radiation oncologist using the Radiation Therapy Oncology Group (RTOG) radiation toxicity guideline. Results: There was no significant relationship between the development of any degree of RD and gender, concomitant chemotherapy (CT), pre-RT CT, comorbid disease, RT technique and blood parameters (Hb, Hba1c, ferritin, folic acid and B12). The development of grade 2-3 RD was significantly affected by the number of operations (p=0.032) and total dose of RT (p=0.008). In patients with grade 2/3 RD, the RT dose at which RD first appeared was 20 Gy (range, 14-36); in patients with grade 1 RD, this value was 32 Gy (range, 16-56) (p=0.018). Conclusion: There is no significant relationship between the development of acute radiodermatitis and Hba1c, hemoglobin, ferritin, B12 and folic acid levels. There was a significant correlation between grade of RD and repeated surgery, increase in total RT dose and early onset of RD.

show abstract

Section: Discussionmentioning

confidence: 66%

Factors on development and severity of acute radiodermatitis: prospective single-center study

İnan

Arslan

Aral

et al. 2022

Anatolian Current Medical Journal

View full text Add to dashboard Cite

show abstract

“…Em geral, as manifestações cutâneas aparecem dentro de 10 a 14 dias após o início da e-Acadêmica, v. 3, n. 3, e2033300, 2022 (CC BY 4.0) | ISSN 2675-8539 | DOI: http://dx.doi.org/10.52076/eacad-v3i3.300 radioterapia e observa-se, tipicamente, uma intensificação das lesões em sessões subsequentes, pela exposição contínua à radiação, sem tempo adequado para reparação do dano tecidual. (Rocha et al, 2021;Bontempo et al, 2021) Contudo, as radiodermites podem ser classificadas de acordo com o período de aparecimento em manifestações precoces ou tardias. Os danos precoces ou agudos surgem horas a semanas após a exposição e geralmente possuem melhor prognóstico, podendo evoluir até mesmo com remissão espontânea.…”

Section: Radiodermiteunclassified

“…Neste sentido, sobressaem-se condições como obesidade e presença de mamas volumosas, que potencialmente aumentam a quantidade de dobras cutâneas gerando regiões de maior fricção e fragilidade. (Bontempo et al, 2021) Além disso, fatores relacionados à técnica empregada e o número de sessões também são relevantes. Estudos comprovam que a técnica de radioterapia modulada por intensidade (IMRT) gera resultados mais satisfatórios quando comparada à irradiação convencional, por administrar doses mais homogêneas, evitando pontos quentes de radiação e reduzindo, dessa forma, a quantidade e a intensidade das manifestações cutâneas subsequentes.…”

Section: Fonte: Turke Et Al (2019)unclassified

Rastreamento e caracterização de lesões de pele pré-cancerosas: uma revisão integrativa

Oliveira¹,

Fontenelle²,

Costa³

et al. 2022

EACAD

View full text Add to dashboard Cite

A presente pesquisa objetivou determinar critérios diagnósticos capazes de fundamentar e fomentar o desenvolvimento de programas de rastreio efetivos da população, que apoiem o serviço de saúde pública na identificação precoce destas lesões potencialmente malignas, favorecendo seu prognóstico e auxiliando o diagnóstico diferencial com outras afecções dermatológicas. Este artigo consiste em uma revisão integrativa, de natureza descritiva, realizada com o objetivo de responder à seguinte questão norteadora: “Quais as estratégias de rastreamento das lesões de pele pré-cancerosas e como estas se caracterizam?”. Inicialmente, foram identificados 1706 estudos após a busca nas bases de dados e 8 estudos por buscas secundárias e bases cinzas da literatura. Após triagem, aplicação dos critérios de elegibilidade e análise dos dados coletados, 17 artigos foram incluídos nesta revisão integrativa. Neste estudo, revisou-se um grande volume de evidências existentes e sumarizou-se os principais aspectos que concernem o rastreamento e caracterização de lesões de pele pré-cancerosas. Desta forma, esta revisão de literatura conseguiu elucidar uma importante lacuna de evidências que limitavam o desenvolvimento de definições clínicas bem estabelecidas, essenciais para apoiar o diagnóstico e a decisão terapêutica das lesões pré-cancerosas de pele.

show abstract

“…Patients with breast cancer, head and neck cancer, lung cancer, or sarcoma are more likely to suffer from RD ( Fuzissaki et al, 2019 ; Tinkle et al, 2021 ; Yokota et al, 2021 ; Louie et al, 2022 ). Erythema is the predominant sign among RD patients, while 42 and 15% of patients developed RT-induced grade 3 and 4 skin toxicities characterized by desquamation, ulceration, and pigment changes ( Hu et al, 2018 ; Bontempo et al, 2021 ). The consequences of RD can be serious, including dose reduction or discontinuation of therapy, delayed treatment, diminished esthetic appeal, and significantly impaired quality of life.…”

Section: Introductionmentioning

confidence: 99%

Prevention of Radiodermatitis With Topical Chinese Herbal Medicine: A Systematic Review and Meta-Analysis

Han

Cao

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: Topical Chinese herbal medicine (TCHM) is widely used to prevent radiodermatitis in patients who receive radiation therapy in China. However, evidence regarding its efficacy remains limited. The purpose of the review is to evaluate the effects of TCHM in preventing radiodermatitis.Methods: The protocol of this review was registered in PROSPERO (CRD42020220620). Relevant clinical trials were identified (from January 1, 2010, to April 24, 2022) through 11 electronic databases, including PubMed, SpringerLink, Proquest, the Cochrane Central Register of Controlled Trials, Scopus, the ProQuest Dissertation & Theses Global, PsycINFO, Applied Social Sciences Index and Abstracts, the Chinese National Knowledge Infrastructure Databases, Wangfang Data Knowledge Service Platform, and the Chongqing VIP Chinese Science and Technology Periodical Database. The quality of the included trials was assessed through a risk of bias assessment using Version 2 of the Cochrane risk-of-bias tool (RoB 2.0). We included RCTs that compared TCHM single used or as adjunctive treatment with routine drugs, conventional therapy, or placebo for cancer patients who are about to start radiation therapy and do not possess any type of dermatitis or skin lesions at that time. Primary outcomes of interest were the incidence of radiodermatitis and the grade of radiodermatitis according to the RTOG (Radiation Therapy Oncology Group). Secondary outcomes included the recovery time of skin and mucosa, the occurrence time of radiodermatitis, the radiation dose, quality of life, and adverse events. Data were summarized using risk ratio (RR) calculations and 95% confidence intervals (CI) for binary outcomes or mean difference (MD) with 95% CI for continuous outcomes. Certainty of the evidence was assessed according to the GRADE criteria.Results: In this review, 38 randomized controlled trials (RCTs) were included. Risk of bias assessment through RoB 2.0 showed that two studies were rated as low risk, two studies were rated as high risk, and the rest were rated as having some concerns. Compared with routine drugs, TCHM may have an advantage in reducing RTOG grading (RR = 0.46, 95%CI 0.35–0.60), decreasing the recovery time of radiodermatitis (MD = −2.35, 95%CI 3.58 to −1.12 days), delaying the occurrence of radiodermatitis (MD = 2.36, 95%CI 1.74–2.98), and improving the quality of life of patients (RR = 1.46, 95%CI 1.03–2.06). Compared with conventional therapy, TCHM may also have an advantage in decreasing the grade of RTOG (RR = 0.28, 95%CI 0.21–0.38).Conclusion: Current low evidence revealed that TCHM may have better efficacy in the prevention of radiodermatitis; however, more high-quality RCTs are still warranted to testify this conclusion.Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020220620), identifier (PROSPERO 2020 CRD42020220620).

show abstract

Acute radiodermatitis in cancer patients: incidence and severity estimates

Cited by 22 publications

References 23 publications

Factors on development and severity of acute radiodermatitis: prospective single-center study

Factors on development and severity of acute radiodermatitis: prospective single-center study

Rastreamento e caracterização de lesões de pele pré-cancerosas: uma revisão integrativa

Prevention of Radiodermatitis With Topical Chinese Herbal Medicine: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About